Johnson & Johnson / 强生

Johnson & Johnson appears in E235｜20年内CAR-T治愈癌症？与刘诚博士聊聊癌症治疗的底层哲学 through its collaboration with Legend Biotech / 南京传奇 on a multiple-myeloma CAR-T product. The source uses that partnership as a commercialization example rather than as a broad company profile.

In the episode, the Legend-Johnson & Johnson case supports the claim that ex vivo CAR-T can become a major drug business in blood cancers even while manufacturing remains expensive. It also shows why big pharma interest in In Vivo CAR-T is commercially legible: if CAR-T efficacy is strong but Ex Vivo CAR-T Manufacturing is the bottleneck, moving manufacturing into the patient could expand access and margins.

130. 谁才是生物医药行业发展的核心驱动力？兼谈创新药产业链的角色分工 adds Johnson & Johnson as a multinational pharma example with deep disease-area accumulation, including multiple myeloma in the source’s account. The episode uses that depth to explain Global Pharma Commercialization: MNC value comes from repeated clinical, commercial, and portfolio execution, not only from discovering first molecules.

156.生物医药的2026：当市场不再为BD躁动，中国药企的星辰大海才刚刚展开 adds the competitive pressure angle: Johnson & Johnson’s multiple-myeloma portfolio, including TCE combinations, is described as pressuring the CAR-T market and affecting Legend Biotech sentiment.

Key Claims

• Johnson & Johnson is linked to a CAR-T commercial success case in multiple myeloma.
• The source uses the case to show treatment-line movement: strong efficacy can push a product from late-line use toward earlier-line therapy.
• The company is part of the episode’s broader big-pharma context around oncology cell therapy.
• Episode 130 uses Johnson & Johnson to illustrate therapeutic-area depth as part of MNC capability.
• Episode 156 adds that an MNC with disease-area depth can pressure a partner-linked CAR-T asset through adjacent modalities such as TCEs.

Connections

• Legend Biotech / 南京传奇 - partner and Chinese biotech commercialization case.
• CAR-T Cell Therapy and Ex Vivo CAR-T Manufacturing - therapy route behind the source’s commercial example.
• In Vivo CAR-T - adjacent route whose attractiveness is partly explained by ex vivo manufacturing costs.
• Global Pharma Commercialization and Clinical Development Capability - MNC role added by episode 130.
• T-Cell Engagers and Biotech BD Data Validation Phase - episode 156 modality-competition context.